Jefferies Financial Group reaffirmed their buy rating on shares of ConvaTec Group (LON:CTEC – Free Report) in a report issued on Wednesday morning, Marketbeat Ratings reports. Jefferies Financial Group currently has a GBX 300 price objective on the stock.
Several other analysts have also weighed in on CTEC. Citigroup dropped their target price on shares of ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a report on Monday, May 18th. UBS Group reaffirmed a “buy” rating and issued a GBX 375 price target on shares of ConvaTec Group in a report on Monday, May 18th. JPMorgan Chase & Co. lowered their price objective on shares of ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a report on Wednesday, April 8th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 340 price target on shares of ConvaTec Group in a report on Tuesday, April 21st. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 306.
Check Out Our Latest Stock Report on CTEC
ConvaTec Group Price Performance
Insider Transactions at ConvaTec Group
In other news, insider Jonny Mason acquired 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were purchased at an average cost of GBX 201 per share, for a total transaction of £100,500. Also, insider Tobias Hestler acquired 50,000 shares of ConvaTec Group stock in a transaction dated Thursday, August 6th. The shares were acquired at an average price of GBX 226 per share, with a total value of £113,000. 0.98% of the stock is owned by company insiders.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Recommended Stories
- Five stocks we like better than ConvaTec Group
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
